Search

Dr. Rudensky studies the development of white blood cells called T lymphocytes, which participate in the immune system response to infection. He joined the Sloan Kettering Institute in 2009.

… Wednesday, September 26, 2012 Summary Dr. Rudensky studies the development of white blood cells called T lymphocytes, which participate in the immune system response to infection. He joined the Sloan Kettering Institute in 2009. Alexander Y. Rudensky has been appointed the new Chair of the Immunology

Leukemia patients may do better on CAR T cell therapy when they are treated early, before their disease relapses.

… Monday, April 3, 2017 Summary For patients with leukemia who relapse after chemotherapy, treatment options have traditionally been limited. At MSK, an experimental immunotherapy called CAR T therapy has expanded options for these patients. New research data presented at this year’s annual meeting of

Evidence from a recent study, led by MSK urologic surgeon, Behfar Ehdaie, MD, MPH, indicates that more patients with favorable Grade Group 2 prostate cancer can be successfully managed with active surveillance and achieve acceptable oncologic outcomes, even if later treatment is required.

… Friday, October 25, 2024 Growing evidence indicates that more patients with favorable Grade Group 2 prostate cancer can be successfully managed with active surveillance and achieve acceptable oncologic outcomes, even if later treatment is required. For the past five years, a team of MSK researchers has

Learn more from Andrea Cercek about a new study showing that colorectal cancer rates are increasing in younger people.

… Tuesday, February 28, 2017 Summary MSK expert Andrea Cercek discusses findings from a new study showing rising colorectal cancer rates among people in their 20s and 30s. Though the overall incidence of colorectal cancer has been on the decline in the US for years, it is increasing among individuals in

Read about a new CAR T cell therapy now approved for marginal zone lymphoma (MZL).

… Friday, December 12, 2025 Marginal zone lymphoma is a slow-growing, rare form of  non-Hodgkin lymphoma that usually responds well to initial therapies. But in some patients, the disease keeps returning despite multiple treatments. Now the U.S. Food and Drug Administration (FDA) has approved a new therapy

Meet Jaap-Jan “J. J.” Boelens, who joined MSK Kids in 2018 as Chief of the Stem Cell Transplantation and Cell Therapy Service.

… Monday, October 7, 2019 Jaap-Jan “J. J.” Boelens joined MSK Kids in 2018 as Chief of the Stem Cell Transplantation and Cell Therapy Service. Some of our MSK Kids patients asked him the questions they were most curious about. You’re a new doctor here at MSK Kids. Where did you come from? — James, 4 I

Nationally known cancer researcher and clinician Craig B. Thompson was named the new President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center in August 2010. He also becomes President of Gerstner Sloan Kettering Graduate School of Biomedical Sciences.

… Wednesday, December 15, 2010 In August 2010, nationally known cancer researcher and clinician Craig B. Thompson was named the new President and Chief Executive Officer of Memorial Sloan Kettering Cancer Center. He succeeded Harold Varmus, now Director of the National Cancer Institute. Dr. Thompson also

Cancer doesn’t stop for a pandemic, but as local governments around the nation mandated the stoppage of elective surgery, Memorial Sloan Kettering Cancer Center (MSK) surgeons had to consider several critical questions.

… Tuesday, May 12, 2020 Cancer doesn’t stop for a pandemic, but as local governments around the nation mandated the stoppage of elective surgery, Memorial Sloan Kettering Cancer Center (MSK) surgeons had to consider several critical questions: What is elective cancer surgery, and what is essential cancer

Total gastrectomy is indicated for patients with stomach cancer gene mutations regardless of family history.

… Monday, November 9, 2020 Risk-reducing prophylactic total gastrectomy may be warranted for patients with pathogenic or likely pathogenic CDH1 variants and a family history of gastric cancer or lobular breast cancer. Moreover, it should be considered for patients with CDH1 variants who do not have a family

For the first time, a genetic link specific to risk of childhood leukemia has been identified, according to a team of researchers from Memorial Sloan Kettering Cancer Center, St. Jude Children’s Research Hospital, University of Washington, and other institutions.

… Sunday, September 8, 2013 For the first time, a genetic link specific to risk of childhood leukemia has been identified, according to a team of researchers from Memorial Sloan Kettering Cancer Center, St. Jude Children’s Research Hospital, University of Washington, and other institutions. The discovery